ethylisopropylamiloride has been researched along with Leukemia, Erythroblastic, Acute in 1 studies
ethylisopropylamiloride: structure in first source
ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.
Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acevedo-Olvera, LF | 1 |
| Diaz-Garcia, H | 1 |
| Parra-Barrera, A | 1 |
| Caceres-Perez, AA | 1 |
| Gutierrez-Iglesias, G | 1 |
| Rangel-Corona, R | 1 |
| Caceres-Cortes, JR | 1 |
1 other study available for ethylisopropylamiloride and Leukemia, Erythroblastic, Acute
| Article | Year |
|---|---|
Inhibition of the Na+/H+ antiporter induces cell death in TF-1 erythroleukemia cells stimulated by the stem cell factor.
Topics: Amiloride; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; | 2015 |